GPhC Warning Issued Over Unsafe Mounjaro Prescribing at an Unregulated Aesthetic Clinic

Date of Decision: July 16, 2026

Registrant's Role: Pharmacist

Allegations:

• The registrant prescribed the high-risk injectable weight-loss medicine Mounjaro without requesting face-to-face consultations, contacting patients directly, or obtaining sufficient information about their physical health to assess whether continued treatment was clinically appropriate.
• The registrant relied principally on screenshots supplied by a non-clinical colleague working within an unregulated aesthetic clinic, rather than personally accessing and reviewing the patients’ clinical records.
• The registrant did not contact patients’ GPs or obtain other independent evidence confirming their medical histories, treatment journeys, or previous weight-loss progress.
• The registrant did not give proper consideration to the risks of prescribing large quantities of weight-loss medication to patients who might be vulnerable or at risk of medication misuse, abuse, or dependence.
• The registrant failed to ensure that appropriate safety-netting arrangements were in place for patients receiving high-risk medication requiring continuing monitoring and management.
• The prescriptions did not accurately identify the organisation or entity issuing them and did not contain sufficient contact information for the prescriber.

Outcome: Warning

GPhC Standards Breached:

• Standard 1 – Provide person-centred care.
• Standard 2 – Work in partnership with others.
• Standard 5 – Use professional judgement.
• Standard 9 – Demonstrate leadership.

Case Summary

Original Case Document